Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
Status:
Recruiting
Trial end date:
2023-12-15
Target enrollment:
Participant gender:
Summary
This phase II trial studies the effect of talazoparib with androgen deprivation therapy and
abiraterone in treating castration sensitive prostate cancer patients. Talazoparib is an
inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes
damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing
them to die. PARP inhibitors are a type of targeted therapy. Androgen can cause the growth of
prostate tumor cells. Degarelix, leuprolide acetate, bicalutamide, goserelin acetate, and
abiraterone lowers the amount of androgen made by the body. This may help stop the growth of
tumor cells that need androgen to grow. Giving talazoparib with androgen deprivation therapy
and abiraterone may improve cancer control for patients with castration sensitive prostate
cancer.